• Trending
  • Latest
    Sign in Sign up
    • Log In
    • Register
    • Home
    • Discover
    • Experts
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Home
    • Discover
    • Experts
    • Learning Lab
    • Mashup Score: 0
      ASCO 2025: FGFR3 Alteration Status and Outcomes with Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma - 16 day(s) ago

      ASCO 2025, bladder cancer, Metastatic Urothelial Carcinoma, FGFR3 alteration, Immune Checkpoint Inhibitors in Patients with Metastatic Urothelial Carcinoma, predictive markers for bladder cancer.

      Source: www.urotoday.com
      Categories: General Medicine News
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        https://t.co/ZGqp827N84 via @urotoday

    • Mashup Score: 8
      100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7 - OncoDaily - 8 month(s) ago

      100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7 / 100 Influential Women in Oncology, Alessandra Curioni,

      Source: oncodaily.com
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        RT @oncodaily: 100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 7 https://t.co/0WBL8nfRL8 T…

    • Mashup Score: 46
      Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial - 8 month(s) ago

      Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of

      Source: www.businesswire.com
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Huge congrats to @neerajaiims & team on this huge news of OS improvement with talazoparib-enza mCRPC in TALAPRO-2 trial! @montypal @PGrivasMDPhD @AzadOncology @NeliMUlrich @DrChoueiri @Huntsman_GU https://t.co/8AOGn1RZJ3

    • Mashup Score: 46
      Pfizer’s TALZENNA® in Combination with XTANDI® Prolongs Overall Survival in Phase 3 TALAPRO-2 Trial - 8 month(s) ago

      Pfizer Inc. (NYSE: PFE) today announced positive topline results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of

      Source: www.businesswire.com
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Huge congrats to @neerajaiims & team on this huge news of OS improvement with talazoparib-enza mCRPC in TALAPRO-2 trial! @montypal @PGrivasMDPhD @AzadOncology @NeliMUlrich @DrChoueiri @Huntsman_GU https://t.co/8AOGn1RZJ3

    • Mashup Score: 8
      Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce - PubMed - 10 month(s) ago

      As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed …

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Must read on primary & acquired resistance to IO developed during the inaugural panel meeting. https://t.co/UtnR2WM56q

    • Mashup Score: 8
      Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce - PubMed - 10 month(s) ago

      As the field of cancer immunotherapy continues to advance at a fast pace, treatment approaches and drug development are evolving rapidly to maximize patient benefit. New agents are commonly evaluated for activity in patients who had previously received a programmed death receptor 1 (PD-1)/programmed …

      Source: pubmed.ncbi.nlm.nih.gov
      Categories: General Medicine News, Oncologists1
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Must read on primary & acquired resistance to IO developed during the inaugural panel meeting. https://t.co/UtnR2WM56q

    • Mashup Score: 33
      Program Guide – ASCO Meeting Program Guide - 1 year(s) ago

      Shilpa Gupta Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Shilpa Gupta, Thomas Powles, Mairead Kearney, Laura Panattoni, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal, Silke Guenther, Nuno Costa, Enrique Grande Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom, The Healthcare Business of Merck KGaA,

      Source: meetings.asco.org
      Categories: General Medicine News, Oncologists2
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Glad to present our work on physician reported 1L tx patterns 5 European countries. @ASCO #ASCO24 @drenriquegrande @tompowles1 👉 >75% pts offered systemic 1L tx 👉advanced age (> med 74 yr) was a major criteria for not offering Tx @CleClinicMD https://t.co/DLopQif809 https://t.co/ubG3aMxAnj

    • Mashup Score: 33
      Program Guide – ASCO Meeting Program Guide - 1 year(s) ago

      Shilpa Gupta Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH Shilpa Gupta, Thomas Powles, Mairead Kearney, Laura Panattoni, Natalie Land, Thomas Flottemesch, Patrick Sullivan, Melissa Kirker, Murtuza Bharmal, Silke Guenther, Nuno Costa, Enrique Grande Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, Barts Cancer Institute, Experimental Cancer Medicine Centre, Queen Mary University of London, St Bartholomew’s Hospital, London, United Kingdom, The Healthcare Business of Merck KGaA,

      Source: meetings.asco.org
      Categories: General Medicine News, Oncologists2
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Glad to present our work on physician reported 1L tx patterns 5 European countries. @ASCO #ASCO24 @drenriquegrande @tompowles1 👉 >75% pts offered systemic 1L tx 👉advanced age (> med 74 yr) was a major criteria for not offering Tx @CleClinicMD https://t.co/DLopQif809 https://t.co/ubG3aMxAnj

    • Mashup Score: 11
      PeerView - Candid Conversations on Modern Urothelial Cancer Management: Personalizing Patient Care Using the Latest Evidence and Innovative Therapeutic Strategies - 1 year(s) ago

      See the latest #BladderCancer live event from @PeerView @AndreaNecchi #ASCO24 #MedEd

      Source: lrn.peerview.com
      Categories: General Medicine News, Oncologists2
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        Looking forward to having candid conversations on modern UC management w/ my esteemed colleagues @AndreaNecchi @MichvdHeijden @MattGalsky @ASCO #ASCO24 @BladderCancerUS on Friday, May 31, 7 PM CST! Join us in-person or online! https://t.co/4BmRuOOBXj https://t.co/XjimWk5XmX

    • Mashup Score: 3
      Urology Cancer Summit - 1 year(s) ago

      The First International Urology Cancer Summit is a free and independent educational opportunity open to everyone involved in caring for patients with urologic cancers.

      Source: urologycancersummit.org
      Categories: General Medicine News, Oncologists2
      Tweet Tweets with this article
      • Profile photo of 	shilpaonc
        shilpaonc

        RT @urologysummit: Neeraj Agarwal is one of the #IUCS23 speakers. Discover more here ➡️https://t.co/RXbCFkCa4h #urology #cancer @neerajaiims

    Load More

    Shilpa Gupta

    @shilpaonc

    GU oncologist, clinical trialist @CleclinicMD Tweets my own, RT/Likes not active endorsement.

    ASCO 2025

    Advertisement

    Advertisement

    MashupMD
    © 2025 - Mashup Media LLC
    • Terms of Use
    • Privacy Policy
    • Cookie Settings